Shares of Corcept Therapeutics (CORT-50%) crater on heavy volume in response to its earnings report today that included a disclosure that it was discontinuing Study 14, a Phase 3 clinical trial to assess the efficacy of mifepristone for psychotic depression. The DMC advised the company that continuing the study to its full enrollment would not likely produce a statistically significant result regarding its primary endpoint.